Binoy Yohannan, MD, Mayo Clinic, Rochester, MN, shares insights into a real-world study exploring the outcomes of patients with light chain (AL) amyloidosis treated with a bortezomib-based regimen versus daratumumab-based frontline therapy. Patients in the daratumumab arm demonstrated an improvement in hematologic response and organ response, which translated to a superior event-free and overall survival (EFS; OS). These findings further support the use of daratumumab-based frontline therapy in AL amyloidosis. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
